A A A A
 
Pages
Meet The Team How-Tos Our Supporters How to Participate in Precision Panc Membership Meeting Minutes Remit of Steering Committee Patient Stories Documents Working with the NHS Patient Public Engagement Meetings Governance News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Posts
Precision-Panc Recruits Patient 250 Marking World Pancreatic Cancer Day Precision-Panc working with myTomorrows Precision-Panc Roundtable Final Report New Glasgow Cancer Assays by GPOL and Agilent Technologies Precision-Panc opens site 25! Precision-Panc Summer Newsletter Precision-Panc Recruits Patient 200! Precision-Panc Brochure Royal Bournemouth Hospital Opens Finding the right treatment for the patient CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Menu
 
 
Home | Team Members | Caroline Dive
 


Department:
Senior Group Leader

Institution:
Cancer Research UK Manchester Institute

Caroline Dive

Professor of Pharmacology at the University of Manchester
Deputy Director of the Cancer Research UK Manchester Institute
Director Manchester Cancer Centre for Biomarker Sciences
Co-Director of the CRUK Lung Cancer Centre of Excellence
Non-Clinical Lead Manchester Experimental Cancer Medicine Centre

After completing her PhD studies at the MRC Clinical Oncology and Radiotherapeutics Unit in Cambridge, Caroline moved to Aston University’s School of Pharmaceutical Sciences in Birmingham where she started her own group studying mechanisms of drug induced tumour cell death. She then moved as a Cancer Research Campaign fellow to the Faculty of Life Sciences at The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before moving to the CRUK Manchester Institute in 2003. Here she set up the Clinical and Experimental Pharmacology Group and began to develop biomarkers, and notably liquid biopsies to support personalised medicine interfacing with The Christie Hospital’s Phase I Clinical Trials Unit.

Caroline is currently Senior Group Leader and Deputy Director of the CRUK Manchester Institute and Professor of Cancer Pharmacology at The University of Manchester. She also co-leads the CRUK Lung Cancer Centre of Excellence and is Manchester’s non-clinical lead of their Experimental Cancer Medicines Centre.

Throughout her career, Caroline has attracted several prizes and awards, most notably she was awarded the Pasteur-Weizmann/Servier International Prize in 2012 and in 2016 the AstraZeneca Prize for Women in Pharmacology. She is an elected Fellow of the Academy of Medical Sciences (2015), Fellow of the British Pharmacological Society (2012) and Fellow of the European Academy of Cancer Sciences (2011). In 2017, Caroline was awarded Commander of the Order of the British Empire (CBE) for her services to cancer research.

A challenge facing molecular profiling of PDAC and many other gastrointestinal cancers is that less than 20% of patients have disease that is able to be surgically removed and therefore tumour samples are often too small for analysis. One approach to overcome this problem is analysis of tumour-shed DNA fragments that can be found in patients’ blood (often referred to as a liquid biopsy).

Liquid biopsies offer access to a minimally invasive and routinely available biopsy with clinical potential for measuring predictive biomarkers and for the detection of resistance to treatment and diseases progression.

Caroline and colleagues have developed a sensitive panel-based Next Generation Sequencing (NGS) assay that can identify faulty genes in patient’s blood samples. Analysis of circulating DNA in PDAC blood samples will provide insights into the usefulness of liquid biopsies as a substitute for a tumour biopsy as well as identifying disease progression or resistance to treatment.

© 2019 Precision Panc
Web design by Creatomatic
This site uses cookies.
Configure
 
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.